Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous ACU193 in Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease

NCT04931459 is registered in ClinicalTrials.gov with Acumen Pharmaceuticals as lead sponsor.

NCT NCT04931459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04931459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous ACU193 in Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease
Lead sponsor
Acumen Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
June 21, 2021
Completion date
June 12, 2023
Enrollment
65 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease